Research graph
References from UBQLN4 Is a Prognostic Biomarker in Intrahepatic Cholangiocarcinoma That Is Associated with Cisplatin Resistance. Local targets link to admitted publications; unresolved targets remain external evidence.
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
2023 · External reference
Cholangiocarcinoma 2020: The next horizon in mechanisms and management
10.1038/s41575-020-0310-z · 2020 · External reference
Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival
10.1200/po-25-00402 · 2025 · External reference
Biliary tract cancer
10.1016/s0140-6736(21)00153-7 · 2021 · External reference
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
10.1016/j.jhep.2019.03.013 · 2019 · External reference
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
10.1056/nejmoa2206834 · 2023 · External reference
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial
10.1001/jamaoncol.2021.3836 · 2021 · External reference
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00727-4 · 2023 · External reference
10.1016/j.jhep.2023.03.010
10.1016/j.jhep.2023.03.010 · External reference
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.506 · 2023 · External reference
DNA repair pathways and cisplatin resistance: An intimate relationship
10.6061/clinics/2018/e478s · 2018 · External reference
Cellular processing of platinum anticancer drugs
10.1038/nrd1691 · 2005 · External reference
DNA repair dysregulation from cancer driver to therapeutic target
10.1038/nrc3399 · 2012 · External reference
Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma
10.1002/1878-0261.12929 · 2021 · External reference
UBQLN4 promotes STING proteasomal degradation during cisplatin-induced DNA damage in triple-negative breast cancer
10.1002/ctm2.985 · 2022 · External reference
A Novel Connexin43-interacting Protein, CIP75, Which Belongs to the UbL-UBA Protein Family, Regulates the Turnover of Connexin43
10.1074/jbc.m709288200 · 2010 · External reference
Ubiquitin-independent proteasomal degradation of endoplasmic reticulum-localized Connexin43 mediated by CIP75
10.1074/jbc.m110.170753 · 2010 · External reference
UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors
10.1016/j.cell.2018.11.024 · 2019 · External reference
10.3390/cells11203311
10.3390/cells11203311 · External reference
Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach
10.1007/s12072-019-09954-3 · 2019 · External reference
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
10.1186/gb-2011-12-4-r41 · 2011 · External reference
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
10.1073/pnas.0506580102 · 2005 · External reference
The Molecular Signatures Database (MSigDB) hallmark gene set collection
10.1016/j.cels.2015.12.004 · 2015 · External reference
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas
10.1001/archsurg.1992.01420110083017 · 1992 · External reference
Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma—Does pathologic response mean better outcomes?
10.1016/j.hpb.2023.01.011 · 2023 · External reference
Induced collagen type-I secretion by hepatocytes of the melanoma liver metastasis is associated with a reduction in tumour-infiltrating lymphocytes
10.1002/ctm2.70067 · 2024 · External reference
Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines
10.1016/j.ajpath.2022.05.007 · 2022 · External reference
Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma
10.1002/ctm2.608 · 2021 · External reference
Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments
10.1016/j.mcp.2024.101951 · 2024 · External reference
Intrahepatic cholangiocarcinoma: The AJCC/UICC 8th edition updates
10.21037/cco.2018.07.03 · 2018 · External reference
UBQLN4 is an ATM substrate that stabilizes the anti-apoptotic proteins BCL2A1 and BCL2L10 in mesothelioma
10.1002/1878-0261.13058 · 2021 · External reference
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01
10.1001/jamaoncol.2025.4736 · 2026 · External reference
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
10.1016/j.annonc.2022.09.150 · 2022 · External reference
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
10.1158/1078-0432.ccr-26-0428 · 2026 · External reference
Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Potential Paradigm Shift in Treatment Sequencing
10.1245/s10434-023-13818-4 · 2023 · External reference
10.1186/s12885-025-15203-8
10.1186/s12885-025-15203-8 · External reference
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
10.1016/j.jhep.2025.05.003 · 2025 · External reference
UBQLN4 promotes progression of HCC via activating wnt-β-catenin pathway and is regulated by miR-370
10.1186/s12935-019-1078-5 · 2020 · External reference
UBQLN4 is activated by C/EBPβ and exerts oncogenic effects on colorectal cancer via the Wnt/β-catenin signaling pathway
10.1038/s41420-021-00795-4 · 2021 · External reference
UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway
10.1007/s00432-024-05862-8 · 2024 · External reference
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas
10.1001/archsurg.1992.01420110083017 · ExternalCitation · doi-reference
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial
10.1001/jamaoncol.2021.3836 · ExternalCitation · doi-reference
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01
10.1001/jamaoncol.2025.4736 · ExternalCitation · doi-reference
Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma
10.1002/1878-0261.12929 · ExternalCitation · doi-reference
UBQLN4 is an ATM substrate that stabilizes the anti-apoptotic proteins BCL2A1 and BCL2L10 in mesothelioma
10.1002/1878-0261.13058 · ExternalCitation · doi-reference
Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma
10.1002/ctm2.608 · ExternalCitation · doi-reference
Induced collagen type-I secretion by hepatocytes of the melanoma liver metastasis is associated with a reduction in tumour-infiltrating lymphocytes
10.1002/ctm2.70067 · ExternalCitation · doi-reference
UBQLN4 promotes STING proteasomal degradation during cisplatin-induced DNA damage in triple-negative breast cancer
10.1002/ctm2.985 · ExternalCitation · doi-reference
UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway
10.1007/s00432-024-05862-8 · ExternalCitation · doi-reference
Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach
10.1007/s12072-019-09954-3 · ExternalCitation · doi-reference
Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines
10.1016/j.ajpath.2022.05.007 · ExternalCitation · doi-reference
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
10.1016/j.annonc.2022.09.150 · ExternalCitation · doi-reference
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.506 · ExternalCitation · doi-reference
UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors
10.1016/j.cell.2018.11.024 · ExternalCitation · doi-reference
The Molecular Signatures Database (MSigDB) hallmark gene set collection
10.1016/j.cels.2015.12.004 · ExternalCitation · doi-reference
Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma—Does pathologic response mean better outcomes?
10.1016/j.hpb.2023.01.011 · ExternalCitation · doi-reference
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
10.1016/j.jhep.2019.03.013 · ExternalCitation · doi-reference
10.1016/j.jhep.2023.03.010
10.1016/j.jhep.2023.03.010 · ExternalCitation · doi-reference
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
10.1016/j.jhep.2025.05.003 · ExternalCitation · doi-reference
Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments
10.1016/j.mcp.2024.101951 · ExternalCitation · doi-reference
Biliary tract cancer
10.1016/s0140-6736(21)00153-7 · ExternalCitation · doi-reference
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00727-4 · ExternalCitation · doi-reference
DNA repair dysregulation from cancer driver to therapeutic target
10.1038/nrc3399 · ExternalCitation · doi-reference
Cellular processing of platinum anticancer drugs
10.1038/nrd1691 · ExternalCitation · doi-reference
UBQLN4 is activated by C/EBPβ and exerts oncogenic effects on colorectal cancer via the Wnt/β-catenin signaling pathway
10.1038/s41420-021-00795-4 · ExternalCitation · doi-reference
Cholangiocarcinoma 2020: The next horizon in mechanisms and management
10.1038/s41575-020-0310-z · ExternalCitation · doi-reference
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
10.1056/nejmoa2206834 · ExternalCitation · doi-reference
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
10.1073/pnas.0506580102 · ExternalCitation · doi-reference
Ubiquitin-independent proteasomal degradation of endoplasmic reticulum-localized Connexin43 mediated by CIP75
10.1074/jbc.m110.170753 · ExternalCitation · doi-reference
A Novel Connexin43-interacting Protein, CIP75, Which Belongs to the UbL-UBA Protein Family, Regulates the Turnover of Connexin43
10.1074/jbc.m709288200 · ExternalCitation · doi-reference
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
10.1158/1078-0432.ccr-26-0428 · ExternalCitation · doi-reference
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
10.1186/gb-2011-12-4-r41 · ExternalCitation · doi-reference
10.1186/s12885-025-15203-8
10.1186/s12885-025-15203-8 · ExternalCitation · doi-reference
UBQLN4 promotes progression of HCC via activating wnt-β-catenin pathway and is regulated by miR-370
10.1186/s12935-019-1078-5 · ExternalCitation · doi-reference
Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival
10.1200/po-25-00402 · ExternalCitation · doi-reference
Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Potential Paradigm Shift in Treatment Sequencing
10.1245/s10434-023-13818-4 · ExternalCitation · doi-reference
Intrahepatic cholangiocarcinoma: The AJCC/UICC 8th edition updates
10.21037/cco.2018.07.03 · ExternalCitation · doi-reference
10.3390/cells11203311
10.3390/cells11203311 · ExternalCitation · doi-reference
DNA repair pathways and cisplatin resistance: An intimate relationship
10.6061/clinics/2018/e478s · ExternalCitation · doi-reference
